SmartSTATS, now by arlenda.

SmartSTATS,
now by arlenda.

Back with the team that created them,
and the standards they rely on.

Back with the team that created them, and the standards they rely on.

Trusted by major pharma for nearly two decades.
21 CFR Part 11 qualified. ICH-compliant. Submission-ready.

Trusted by major pharma for nearly two decades. 21 CFR Part 11 qualified. ICH-compliant. Submission-ready.

Software

SmartSTATS suite

Enoval

Validate your analytical procedures and bioassays with confidence, from development to routine, from one lab to another.

Analytical Procedure Validation

Prove that your physico-chemical procedures measures what it should, with the accuracy and precision required for reliable release and stability testing.

Automated validation reporting for physico-chemical procedures (HPLC, GC, UV, ICP, AAS, titration). Computes accuracy, precision, and Total Analytical Error profiles using β-expectation tolerance intervals. Generates submission-ready reports aligned with ICH Q2(R2), ICH Q14, ICH M10, and USP <1210>. Optimized experimental design within the QbD framework.

Bioassay Validation

Demonstrate that your biological assay delivers trustworthy potency results, whether you run an ELISA, a cell-based assay, or a qPCR.

Qualification and validation of biological assays: ELISA, RIA, qPCR, cell-based, microbiological, parallel-line, parallel-curve, and slope-ratio formats. Dedicated potency module for relative potency assays following a lognormal distribution. Reports aligned with USP <1032>, <1033>, and <1034>. Equivalence testing for parallelism and similarity.

Procedure Transfer

Before you transfer a procedure to another lab, know the risk that routine results will fall out of specification, and act on it.

Tolerance interval-based assessment of procedure transfer feasibility between sender and receiver laboratories. Quantifies the risk of future out-of-specification results at the receiving site under routine conditions. Supports all four USP <1224> transfer approaches. Automated protocol and report generation.

Stabelity

Determine how long your product stays within specification, set the right release limits, and detect stability trends before they become problems.

Back with the team that created them, and the standards they rely on.

Long-term and accelerated stability analysis with Arrhenius kinetic modeling and goodness-of-fit diagnostics. Shelf-life estimation, internal release limit computation, and out-of-trend detection. Supports bracketing and matrixing designs. Submission-ready reports aligned with ICH Q1E and the forthcoming consolidated ICH Q1.

SmartSTATS Returns Home
to arlenda

PharmaLex Beglium has transferred ownership of the SmartSTATS suite, Enoval and Stabelity, to Arlenda. For our clients, this is good news: the software has moved back to the team that knows it best, at exactly the moment the industry needs it most.

Arrow illustration

Our roots

arlenda was founded in 2003 by Dr. Bruno Boulanger, whose work has directly shaped the statistical principles now embedded in ICH Q2(R2) and USP <1033>. He is joined by Cédric Dubourg, who has maintained and evolved SmartSTATS since 2010, and Nils Boulanger, AI engineer, who brings the next generation of data science to the suite. Continuity, expertise, and innovation - under one roof.

Illustration

The timing matters

Digitalization and AI are reshaping how analytical and biopharmaceutical work gets done, while regulatory expectations have never been more demanding. Our clients need a partner who understands both sides of that equation, responds quickly, and stays close to their reality.

Values

Built by senior life sciences strategists

Deep experience across clinical development, regulatory strategy, and translational science, combined with advanced expertise in causal inference and Bayesian methods. Over 100 published scientific papers and leadership of the BAYES conference series.

Built by senior life sciences strategists

Deep experience across clinical development, regulatory strategy, and translational science, combined with advanced expertise in causal inference and Bayesian methods. Over 100 published scientific papers and leadership of the BAYES conference series.

Grounded in regulatory reality

Methods aligned with EMA and FDA expectations, built to support real-world submissions and accelerate regulatory pathways.

Grounded in regulatory reality

Methods aligned with EMA and FDA expectations, built to support real-world submissions and accelerate regulatory pathways.

Proven track record from discovery to market

Engagements spanning the full product lifecycle, with demonstrated success bringing therapies from early research through clinical development and commercial launch.

Proven track record from discovery to market

Engagements spanning the full product lifecycle, with demonstrated success bringing therapies from early research through clinical development and commercial launch.

Independent and privately held

We work in your interest, not a shareholder’s. No short-term commercial pressure, no conflicts of interest.

Independent and privately held

We work in your interest, not a shareholder’s. No short-term commercial pressure, no conflicts of interest.

The People Behind Arlenda

Bruno Boulanger, CEO of Arlenda

Bruno Boulanger

CEO

Description

Read more

Bruno is a recognized leader in applied statistics with over 30 years of experience across pharmaceutical and medical device development. He has held senior roles at Eli Lilly and UCB, founded Arlenda in 2003, published over 100 scientific papers, and launched the BAYES conference series.

Gaëlle Martin, Head of QA of Arlenda

Gaëlle Martin

Head of QA

Description

Read more

20+ years in QA leadership. QMS aligned with GMP, GCP, GAMP5, ISO 9001/13485. Computerized system validation and complex GxP projects.

Cédric Dubourg, Head of Software of Arlenda

Cédric Dubourg

Head of Software

Description

Read more

Cédric is the lead developer behind Arlenda's SmartSTATS platform, with nearly two decades of experience across banking, insurance, and pharmaceutical services. He has built and maintained the platform since 2010, covering Java development, web technologies, cloud infrastructure, containerization, database management, and Linux administration. He has kept SmartSTATS running, secure, and evolving for the past fifteen years.

Nils Boulanger, CTO of Arlenda

Nils Boulanger

CTO

Description

Read more

Nils Boulanger is CTO of Arlenda, where he leads AI development and the technical architecture behind the SmartSTATS platform. With a Master's in Data Science Engineering, he builds AI solutions on a foundation of software engineering and applied statistics, designing secure, scalable systems for regulated environments.

Get in touch